Endothelial cell‐derived extracellular vesicles alter vascular smooth muscle cell phenotype through high‐mobility group box proteins
Michael Boyer(Chris O’Brien Lifehouse), Victor Rizzo(University of Iowa), Ariele Baggett(Temple University), Yayoi Kimura(Yokohama City University Medical Center), Tomoko Akiyama(Yokohama City University Medical Center), Kyle Preston(Temple University), Rosario Scalia(Thomas Jefferson University), Satoru Eguchi(University of South Florida)
Cited by 83
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
|Physiological Reviews|2018|1.1k